Insight Molecular Diagnostics Inc. — Director's Dealing 2024

Jul 3, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2024-07-01

Reporting Person: SILVERMAN LOU (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-07-01	Option to Purchase Common Stock	$2.95	A	30000	Acquired	2034-07-01	Common Stock (30000)	Direct

Footnotes

F1: Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.